Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.

Pennisi A, Li X, Ling W, Khan S, Gaddy D, Suva LJ, Barlogie B, Shaughnessy JD, Aziz N, Yaccoby S.

Br J Haematol. 2009 Jun;145(6):775-87. doi: 10.1111/j.1365-2141.2009.07696.x. Epub 2009 Apr 8.

2.

Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.

Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J Jr, Yaccoby S.

Br J Haematol. 2006 Apr;133(1):83-92.

PMID:
16512833
3.

SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.

Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY, Roodman GD, Lentzsch S.

Blood. 2007 Mar 1;109(5):2130-8. Epub 2006 Nov 9.

4.

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.

Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaissé JM.

Leuk Res. 2008 Nov;32(11):1661-8. doi: 10.1016/j.leukres.2008.02.019. Epub 2008 Apr 18.

PMID:
18394701
5.
6.
7.

Bortezomib inhibits human osteoclastogenesis.

von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, Kaiser M, Jakob C, Sterz J, Kleeberg L, Heider U, Sezer O.

Leukemia. 2007 Sep;21(9):2025-34. Epub 2007 Jun 21.

PMID:
17581612
8.

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J.

Br J Haematol. 2002 Feb;116(2):278-90.

PMID:
11841428
9.

Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.

Pennisi A, Ling W, Li X, Khan S, Wang Y, Barlogie B, Shaughnessy JD Jr, Yaccoby S.

PLoS One. 2010 Dec 20;5(12):e15233. doi: 10.1371/journal.pone.0015233.

10.

p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.

He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang J.

Cancer Res. 2012 Dec 15;72(24):6393-402. doi: 10.1158/0008-5472.CAN-12-2664. Epub 2012 Oct 11.

11.

NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.

Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S.

Exp Hematol. 2013 Jun;41(6):547-557.e2. doi: 10.1016/j.exphem.2013.02.008. Epub 2013 Feb 19.

12.

A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.

Kim HJ, Yoon KA, Lee MK, Kim SH, Lee IK, Kim SY.

Life Sci. 2012 Nov 2;91(19-20):928-34. doi: 10.1016/j.lfs.2012.09.009. Epub 2012 Sep 20.

PMID:
23000100
13.

Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis.

Kim MH, Ryu SY, Bae MA, Choi JS, Min YK, Kim SH.

Food Chem Toxicol. 2008 Nov;46(11):3375-82. doi: 10.1016/j.fct.2008.08.016. Epub 2008 Aug 26.

PMID:
18786594
14.

The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.

Huh JE, Jung IT, Choi J, Baek YH, Lee JD, Park DS, Choi DY.

Eur J Pharmacol. 2013 Jan 5;698(1-3):57-66. doi: 10.1016/j.ejphar.2012.08.013. Epub 2012 Sep 14.

PMID:
22985747
15.

Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.

Terpos E.

Leuk Res. 2008 Nov;32(11):1646-7. doi: 10.1016/j.leukres.2008.06.017. Epub 2008 Jul 9. No abstract available.

PMID:
18614229
16.

Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.

Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaissé JM.

Cancer Res. 2005 Nov 1;65(21):9943-52.

17.

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.

Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R, Croucher PI.

Cancer Res. 2007 Jan 1;67(1):202-8.

18.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

19.

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T.

Clin Cancer Res. 2007 Feb 1;13(3):816-23.

20.

Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.

Yonezawa T, Hasegawa S, Asai M, Ninomiya T, Sasaki T, Cha BY, Teruya T, Ozawa H, Yagasaki K, Nagai K, Woo JT.

Eur J Pharmacol. 2011 Jan 15;650(2-3):511-8. doi: 10.1016/j.ejphar.2010.10.048. Epub 2010 Nov 1.

PMID:
21047508

Supplemental Content

Support Center